Frontlight ResearchEarly access
CompletedPhase 3
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
Key facts
- Who runs it
- ModernaTX, Inc.
- Where
- Annapolis, Anniston, Athens, Atlanta, Austin, Banning, Baton Rouge, Beaumont, Binghamton, Bountiful, Cerritos, Charlotte, Chicago, Cincinnati, Columbia, Conroe, Covington, Cullman, Decatur, DeSoto, East Syracuse, Fayetteville, Fremont, Gaffney, Grand Island, Grants Pass, Gulfport, Hallandale, Hendersonville, Hialeah, Houston, Humble, Huntington Beach, Huntsville, Jacksonville, Jupiter, La Mesa, Lake City, Lake Mary, Las Vegas, Lenexa, Lewisville, Little Rock, Mesa, Miami, Miami Lakes, Minneapolis, Morehead City, New Orleans, Newton, Norfolk, Omaha, Overland Park, Palmetto Bay, Pasadena, Pembroke Pines, Philadelphia, Phoenix, Raleigh, Richmond, River Forest, Riverside, Rochester, Rockville, Rolling Hills Estates, Saint Augustine, Salt Lake City, San Antonio, San Diego, San Francisco, Savannah, South Ogden, Spartanburg, Springfield, St Louis, Stockbridge, Sugar Land, Tampa, Tempe, The Villages, Tomball, Troy, Tucson, Tulsa, Valparaiso, Vestal, Waterbury, and Wichita, United StatesSee the 103 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 8,411 people enrolled
- Started
- 17 Apr 2023
- Ended
- 24 Jun 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- mRNA-1010
- Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
- Record updated
- 10 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Investigator has assessed that the participant understands and is willing and physically able to comply with protocol mandated follow up, including all procedures
- For assigned females at birth and of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration; Part A:
- At least 18 years of age inclusive, at the time of signing the informed consent form (ICF); Part B:
- At least 18 and <65 years of age, at the time of signing the ICF; Part C:
- At least 65 years of age or older, at the time of signing the ICF
Who cannot take part
- Participant is acutely ill or febrile (temperature ≥38.0℃elcius [100.4°Fahrenheit]) 72 hours prior to or at the Screening visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window
- Participant has tested positive for influenza by local health authority-approved testing methods within 150 days (for Part A) or 180 days (for Parts B and C) prior to Day 1
- Participant has received systemic immunosuppressants for >14 days in total within 180 days prior to Day 1 (for corticosteroids, ≥10 mg/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. Inhaled, nasal and topical steroids are allowed. Intra-articular and epidural steroid injections are not allowed within 28 days before and/or after study intervention dosing
- Participant has received any vaccine authorized or approved by local health agency ≤28 days prior to study intervention dosing (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after study intervention dosing
- Participant has received a licensed seasonal influenza vaccine within 5 months (150 days) (for part A) or within 6 months (180 days) (for Parts B and C) prior to Day 1
- Participant has participated in any investigational seasonal influenza vaccine study within12 months prior to Day 1
- Participant is not aware whether they have received an influenza vaccine in the most recent influenza season (in the prior 12 months) (for Part A) or since September 2022 (for Parts B and C)
- Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to Day 1 or plans to donate blood products during the study; Note: Other inclusion and exclusion criteria may apply
- Participant has a history of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures
- Reported history of congenital or acquired immunodeficiency, immunosuppressive condition or immune-mediated disease, asplenia, or recurrent severe infections
- Reported history of anaphylaxis or severe hypersensitivity reaction after receipt of mRNA vaccines or any components of the mRNA-1010 or influenza vaccines, including egg protein
- Participant has had close contact with someone with laboratory-confirmed influenza infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu®) within the past 5 days prior to Day 1
Where in United States
- Javara Inc.Annapolis, United States
- Pinnacle Research GroupAnniston, United States
- North Alabama Research Center LLCAthens, United States
- Synexus Clinical Research US Inc - AtlantaAtlanta, United States
- Tekton Research - Austin - PPDSAustin, United States
- Velocity Clinical Research - BanningBanning, United States
- Velocity Clinic Research, Inc.Baton Rouge, United States
- Tekton Research, LLCBeaumont, United States
- Velocity Clinical Research (Binghamton - New York) - PPDSBinghamton, United States
- Cope Family Medicine - CCTBountiful, United States
- Synexus Clinical Research US, Inc. - CerritosCerritos, United States
- Javara IncCharlotte, United States
- Great Lakes Clinical Trials - RavenswoodChicago, United States
- Synexus Clinical Research US Inc.-ChicagoChicago, United States
- CTI Clinical Research CenterCincinnati, United States
- Velocity Clinical Research Inc.Cincinnati, United States
- Velocity Clinical Research, Mt. AuburnCincinnati, United States
- Velocity Clinical Research, ColumbiaColumbia, United States
- Javara inc.Conroe, United States
- Velocity Clinical Research, CovingtonCovington, United States
- Cullman Research CenterCullman, United States
- CenExel iResearch, LLCDecatur, United States
- Epic Medical Research - DeSotoDeSoto, United States
- Velocity Clinical Research, SyracuseEast Syracuse, United States
- Javara Inc.Fayetteville, United States
- Methodist Physicians Clinic / CCT ResearchFremont, United States
- Velocity Clinical Research, GaffneyGaffney, United States
- Velocity Clinical Research - Grand IslandGrand Island, United States
- Velocity Clinical Research, Grants PassGrants Pass, United States
- DelRicht ResearchGulfport, United States
- Velocity Clinical Research, GulfportGulfport, United States
- Velocity Clinical Research, Hallandale BeachHallandale, United States
- DelRicht ResearchHendersonville, United States
- Indago Research and Health CenterHialeah, United States
- NeoClinical ReseaarchHialeah, United States
- DM Clinical ResearchHouston, United States
- DM Clinical ResearchHumble, United States
- Marvel Clinical Research 002, LLCHuntington Beach, United States
- Medical Affiliated Research Center, Inc.Huntsville, United States
- Jacksonville Center for Clinical ResearchJacksonville, United States
- Health Awareness, IncJupiter, United States
- Velocity Clinical ResearchLa Mesa, United States
- Wr-Msra,LlcLake City, United States
- Sandhill Research, LLC d/b/a Accel Research SitesLake Mary, United States
- Sandhill Research, LLC d/b/a Accel Research Sites NetworkLake Mary, United States
- University Clinical Research-DeLand, LLC d/b/a Accel ResearchLake Mary, United States
- Alliance for Multispecialty Research, LLCLas Vegas, United States
- Johnson County Clin-Trials (JCCT)Lenexa, United States
- Epic Clinical ResearchLewisville, United States
- Baptist Health Center for Clinical ResearchLittle Rock, United States
- Desert Clinical Research - CCTMesa, United States
- Clinical Site Partners LLC, dba Flourish ResearchMiami, United States
- Miami Clinical ResearchMiami, United States
- South Florida Research Center, Inc.Miami, United States
- Suncoast Research Associates, LLCMiami, United States
- Floridian Clinical ResearchMiami Lakes, United States
- Clinical Research Institute, Inc - CRNMinneapolis, United States
- Lucas Research, Inc.Morehead City, United States
- Delricht ResearchNew Orleans, United States
- Alliance for Multispecialty Research, LLCNewton, United States
- Velocity Clinical Research (Norfolk - Nebraska) - PPDSNorfolk, United States
- Midwest Regional Health Services - LLC - CCTOmaha, United States
- Velocity Clinical Research (Omaha - Nebraska) - PPDSOmaha, United States
- Velocity Clinical Research, Inc.Omaha, United States
- Velocity Clinical Research, Inc.Overland Park, United States
- Innovation Medical Group LLCPalmetto Bay, United States
- Pasadena Clinical TrialsPasadena, United States
- Suncoast Research Associates LLCPembroke Pines, United States
- DM Clinical Research - Philadelphia - ERNPhiladelphia, United States
- Foothills Research Center - CCTPhoenix, United States
- M3 Wake Research, Inc.Raleigh, United States
- Clinical Research Partners LLC - Richmond - ERNRichmond, United States
- DM Clinical ResearchRiver Forest, United States
- Artemis Institute For Clinical Research LLC - Riverside - HeadlandsRiverside, United States
- Rochester Clinical Research, IncRochester, United States
- Velocity Clinical Research, RockvilleRockville, United States
- Peninsula Research Associates - CRNRolling Hills Estates, United States
- St. Johns Center for Clinical Research - ERNSaint Augustine, United States
- J. Lewis Research, Inc. / Foothill Family ClinicSalt Lake City, United States
- Olympus Family Medicine/CCT ResearchSalt Lake City, United States
- Clinical Trials of Texas IncSan Antonio, United States
- Acclaim Clinical ResearchSan Diego, United States
- Optimal Research, LLCSan Diego, United States
- Optimus Medical GroupSan Francisco, United States
- Velocity Clinical Research - SavannahSavannah, United States
- South Ogden Family Medicine Ogden Clinic/CCT ResearchSouth Ogden, United States
- Spartanburg Medical ResearchSpartanburg, United States
- Bio-Kinetic Clinical Applications, LLC dba QPS-MOSpringfield, United States
- Sundance Clinical Research, LLCSt Louis, United States
- CRA, Headlands LLCStockbridge, United States
- DM Clinical ResearchSugar Land, United States
- Javara Inc.Sugar Land, United States
- New Tampa Health, IncTampa, United States
- Fiel Family & Sports Medicine - PC - CCTTempe, United States
- Synexus Clinical Research US, Inc. - The VillagesThe Villages, United States
- DM Clinical ResearchTomball, United States
- Oakland Medical ResearchTroy, United States
- Noble Clinical ResearchTucson, United States
- DelRicht ResearchTulsa, United States
- Velocity Clinical Research, ValparaisoValparaiso, United States
- Velocity Clinical Research, Inc.Vestal, United States
- Chase Medical Research LLC - WaterburyWaterbury, United States
- Alliance for Multispecialty Research LLCWichita, United States
About the trial
What the trial wants to find out
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
The 2 groups in the trial
- mRNA-1010Treatment being tested
Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
- Licensed Quadrivalent Inactivated Seasonal Influenza VaccineExisting treatment, for comparison
Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Stratified, Observer-Blind, Active-Controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of mRNA-1010 Seasonal Influenza Vaccine in Adults 18 Years and Older
- Publications
- Record updated
- 10 July 2025